Finland-based Evondos Group, a leading provider of automated medication dispensing services in Northern Europe, is accelerating its international expansion as structural pressures on home care systems intensify across Europe and the UK.
Founded in 2008 by Mika Apell, Evondos has developed technology designed to improve medication adherence, reduce dispensing errors, and ease the burden on overstretched home care providers. Its Evondos and Medido platforms support more efficient care delivery while generating cost savings and greater flexibility for healthcare personnel.
Following the launch of its first fully operational service in 2014, the company expanded across the Nordics, establishing a presence in Finland, Norway, Sweden and Denmark. Ownership has evolved alongside its growth, with Serendipity Partners becoming the main shareholder in 2017, before Nordic growth equity investor Verdane acquired the business in 2020.
Evondos entered the Dutch market in 2023 through the acquisition of Vitavanti Group, bringing Medido – the country’s leading automated medication dispenser – into the group. More recently, the company has begun building momentum in the UK, where it established a local subsidiary in 2025 and has already demonstrated measurable cost savings in pilot deployments.
With the appointment of a UK country manager in 2026 and a strengthened leadership team, Evondos is now targeting further geographic expansion beyond its Northern European base, combining organic growth with selective M&A.
Investors in Healthcare spoke to CEO Frans Cromme about the structural drivers behind rising demand for home care, how technology can alleviate workforce shortages, and why the UK may be approaching a tipping point for digital adoption.
IIH: What are the key pressures facing home care systems today?
Frans Cromme: Across Western Europe and the US, three structural trends are converging: ageing populations driving a sharp increase in demand for care; a shortage of nurses in most markets – a supply gap that is widening; and a shift in the delivery of care. Ten to 15 years ago, many elderly people spent their final years in care homes, but increasingly that care is being delivered at home.
Taken together, these trends create a significant challenge: how do you provide healthcare and social care to more people, at home, with a smaller professional workforce?
IIH: How does Evondos’ technology change the economics of home care delivery?
FC: We started by looking at where nurses spend their time and how technology could improve efficiency.
Today, a large proportion of their workload is not direct patient care; it is spent on administration, travel, and planning. That creates both a capacity issue and a job satisfaction issue.
Our focus has been on automating repetitive and administrative tasks so nurses can spend more time on patient care. That can increase the number of patients they can serve and improve the quality of care they provide.
IIH: What does the core offering look like today?
FC: We currently have around 40,000 systems deployed – across six markets – that ensure patients receive the right medication at the right time through automated dispensing devices.
The systems alert patients when medication is due and escalate if doses are missed, either to a nurse, a family member or another contact. As a result, medication adherence exceeds 99.5%.
This is particularly important for patients with conditions such as dementia or Parkinson’s, where missing medication can have severe consequences.
IIH: How does the platform evolve beyond medication dispensing?
FC: Medication compliance is just the starting point. What we are building is effectively a connected hub in the home.
Through that hub, we can integrate additional technologies such as blood pressure monitoring, sleep tracking, fall detection and general wellbeing checks. These are all areas where nurses currently spend time that could be supported remotely.
Our vision is to combine these data streams into a single platform, enabling more effective remote patient monitoring and reducing unnecessary visits.
IIH: Where do you see the biggest growth opportunities?
FC: Across three main areas: expanding within existing markets – even in the Netherlands, for example, only a fraction of eligible patients currently use our technology; cross-selling additional solutions to existing customers by building out a broader remote monitoring ecosystem; and geographic expansion. We are well established in the Nordics and the Netherlands, and we are scaling in the UK. Expansion into other European markets and North America will follow.
IIH: How important is the UK market to your growth strategy?
FC: The UK is a key market, but it takes time.
The Nordics and the Netherlands are further ahead in adopting a ‘digital-first’ approach. In those markets, care providers actively look at how technology can solve problems before deploying human resources. The UK has been slower, but it is catching up quickly.
We’ve been active in the UK for around five years, and we are now starting to generate revenues. The main challenge has been the lack of established reimbursement pathways and integration into the NHS system. But, one advantage of dealing with the NHS is that once a direction is set, adoption can scale rapidly. We are starting to see strong momentum build, particularly as digital tools become more integrated into care planning.
IIH: What is required to achieve scale in the UK?
FC: Local evidence is critical.
You need to demonstrate, within the UK system, that your technology saves time and improves outcomes. Showing how solutions like our combined medication dispensing and video capability can reduce nurse visits and improve efficiency.
Once that evidence is established, it becomes much easier to scale. We are now at that point.
IIH: What is your long-term strategy as CEO?
FC: Medication dispensing is still an emerging category in Europe.
There are a few players, particularly in the US, but in markets such as the UK, France and Germany, there are no dominant players. That means we are effectively building the market ourselves. That takes time but also gives us a strong first-mover advantage.
Evondos is transitioning from a Nordic-focused hardware company to an international digital health platform. That involves scaling geographically, expanding our product offering, and building an organisation capable of operating across multiple healthcare systems.
The focus for us now is on accelerating growth, both organically and potentially through partnerships.
IIH: How does Verdane support that growth?
FC: Verdane brings both capital and operational expertise. They have strong resources in areas such as AI, cybersecurity and marketing, which we can leverage directly. They also move quickly in decision-making, which is critical for scaling a business like ours.
Importantly, they focus heavily on organisational development, not just the financial metrics. That ensures the team is ready for the next stage of growth.
IIH: Where do you expect the business to be in five years?
FC: We aim to be active across most European markets and to have established a presence in North America.
Our revenue base will also be more diversified. Today, almost all revenue comes from medication dispensing, but we expect 20–30% to come from broader digital health services such as remote monitoring and virtual care.
Ultimately, the goal is to build a comprehensive platform that supports home care delivery at scale.
